Home/Filings/4/0001628280-24-042545
4//SEC Filing

Mostafa Adam S. 4

Accession 0001628280-24-042545

CIK 0001501697other

Filed

Oct 7, 8:00 PM ET

Accepted

Oct 8, 4:44 PM ET

Size

7.0 KB

Accession

0001628280-24-042545

Insider Transaction Report

Form 4
Period: 2024-10-04
Mostafa Adam S.
Chief Financial Officer
Transactions
  • Award

    Common Stock

    2024-10-04+230,645230,645 total
  • Sale

    Common Stock

    2024-10-07$0.55/sh230,645$126,9010 total
Footnotes (3)
  • [F1]Represents shares earned upon the vesting of performance-based restricted stock units. The Compensation Committee of the Board of Directors of the Issuer certified the achievement of the performance condition.
  • [F2]These transactions were made pursuant to a rule 10b5-1 trading plan adopted by the Reporting Person on June 28, 2024.
  • [F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $0.5144 to $0.6036, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Issuer

X4 Pharmaceuticals, Inc

CIK 0001501697

Entity typeother

Related Parties

1
  • filerCIK 0001738081

Filing Metadata

Form type
4
Filed
Oct 7, 8:00 PM ET
Accepted
Oct 8, 4:44 PM ET
Size
7.0 KB